Hypertension- a Companion to Braunwald's Heart Disease

Section 1: Epidemiology & Pathophysiology 1. Epidemiology 2. Genetics of Hypertension 3. Pathogenesis of Hypertension Section 2: Diagnosis 4. Definition of Hypertension 5. Measurement of Blood 6. Home BP Measurements 7. ABPM 8. Secondary Hypertension: Renovascular Hypertension 9. Secondary Hypertension: Mineralocorticoid Excess States 10. Secondary Hypertension: Pheochromocytoma 11. Secondary Hypertension: Sleep Apnea 12. Rare Unusual Diagnoses Section 3: Risk Stratification 13. Natural History of (Untreated) Hypertension 14. The Special Problem of (Isolated) Systolic Hypertension 15. Assessment of Target Organ Damage 16. Prediction of Global Cardiovascular Risk Section 4: Treatment 17. Lifestyle Modifications 18. Diuretics 19. Beta-blockers 20. ACE-inhibitors and Angiotensin II Receptor Blockers 21. Calcium Antagonists 22. Alpha-Blockers 23. Other (Newer) Drugs, including centrally-acting drugs, aldosterone antagonists, vasopeptidase inhibitors, and endothelin antagonists Section 5: Outcome Studies 24. Design of Outcomes Studies 25. Meta-analyses Section 6: Hypertension and Concomitant Diseases 26. Ischemic Heart Disease 27. Heart Failure 28. Kidney Disease 29. Transplant Hypertension 30. Obesity 31. Peripheral Vascular Disease 32. Cerebrovascular Disease 33. Diabetes 34. Dyslipidemia Section 7: Special Populations & Special Situations 35. Pregnancy-Related Hypertension 36. Children and Adolescents 37. Elderly 38. Blacks 39. Hispanics 40. East Asians 41. South Asians 42. Refractory Hypertension 43. Peri-operative Hypertension 44. Emergencies and Urgencies Section 8: Hypertension Treatment in the Future 45. Hypertension Disease Management Service 46. Hypertension Genomics 47. Approval Process for Antihypertensive Drugs-US and International Section 9: Guidelines 48. US and Canadian Guidelines 49. European Guidelines, including BHS and ESH/ESC